Investor Presentation: First Nine Months of 2020
102
Investor presentation First nine months of 2020
North America Operations at a glance.
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Novo Nordisk®
Million
DKK
billion
760
70
13%
500
60
18%
400
50
40
30
56
63
89
56
48
20
20
First nine months
2020
Sales
(mDKK)
Growth²
70%
Long-acting insulin³
5,836
(34%)
60%
Premix insulin4
421
(22%)
GLP-1
50%
Fast-acting insulin5
5,912
(11%)
39%1
300
Human insulin
1,323
10%
40%
Total insulin
13,492
(22%)
200
30%
GLP-16
6%1
21,964
27%
Insulin
Other Diabetes care?
806
31%
20%
100
Diabetes care
36,262
3%
10
15%1
OAD 10%
Obesity care
2,612
4%
0
2019
(SaxendaⓇ)
2030
0
Aug
2045
2015
0%
Population with diabetes
Diabetes growth rate
GLP-1 MS -Insulin MS
Aug
2020
OAD MS
Diabetes & Obesity
38,874
3%
care
Biopharm³
Total
5,535
44,409
(2%)
2%
International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 9th Edition 2019
1 CAGR calculated for 5-year period
Competitor insulin value market shares, as of Aug 2020: Novo Nordisk 44%,
Eli Lilly 31% and Sanofi 26%; Competitor GLP-1 value market shares, as of
Aug 2020: Novo Nordisk 49%, Eli Lilly 44% and AstraZeneca 7%
OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT, Aug 2020
value figures
2 At constant exchange rates ³ Comprises Tresiba®, XultophyⓇ and LevemirⓇ; 4
Comprises NovoMix®; 5 Comprises FiaspⓇ and NovoRapidⓇ: 6 Comprises
VictozaⓇ and Ozempic®: 7 Comprises Novo NormⓇ and needles; 8 Comprises
primarily NovoSeven®, Novo Eight®, NovoThirteen®, Refixia®, Norditropin®,
Vagifem® and ActivelleⓇView entire presentation